



Strong 13% 2006 full-year growth

2006 4th quarter sales up 13%

€ millions	2006	2005	% increase
Quarter 4 sales	37.46	33.14	13%
France, including overseas dependencies	19.33	16.18	19%
Subsidiaries (1)	14.09	13.30	6%
Distributors (2)	4.04	3.66	10%
Cumulative sales at end December	126.55	112.04	13%
France, including overseas dependencies	66.51	57.79	15%
Subsidiaries (1)	46.05	41.75	10%
Distributors (2)	13.99	12.50	12%

(1) Germany, Belgium, Italy, Spain and Portugal.

(2) Other countries

2006 4th quarter growth (13%) remained vigorous, due primarily to the continuing attraction of new patients in France. However, growth in Germany was slow in an overall stable market.

Over the full financial year, organic growth was 13%.

- France (up 15%): market development remained strong, sustained by an expanded service offer.
- Subsidiaries (up 10%): growth was limited in Germany but was otherwise strong in other subsidiaries. The integration of IPI, acquired in 2005, was successfully completed in Spain and Portugal.
- Distributors (up 12%): sales recovery in North Africa and the Middle East managed to offset slower growth in Eastern Europe.

In order to enhance the efficiency of its operations in now mature markets, **Stallergenes, through its Prague subsidiary, took control of sales and marketing activities in the Czech Republic and Slovakia.** Corresponding sales will be reported under "Subsidiaries" from 2007. The good level of sales should enable the Group to report an operating profit similar to 2005, in spite of the substantial increase in R&D expenditures related to the tablet programme and the promotion costs associated with the launch of **Oralair® Grasses**, planned for 2007.

About STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

With headquarters in France, Stallergenes markets its products in approximately 40 countries.

Stallergènes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP



STALLERGENES

Albert SAPORTA - Chairman
Christian THIRY – Chief Financial Officer
Tél : +33 (0)1 55 59 20 95
investorrelations@stallergenes.fr

PAVIE FINANCE

Lucile de FRAGUIER
Investor & Analyst Relations
Tel: + 33 (0)1 42 15 04 39
contact@pavie-finance.com